Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

 
Press Releases
  Date Title View
Jun 20, 2005
OXiGENE Provides Update on Vascular Targeting Programs in Ophthalmology

WALTHAM, Mass.--(BUSINESS WIRE)--June 20, 2005--OXiGENE, Inc. (NASDAQ and XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and ocular neovascular diseases, today provided a mid-year update on the progress of its programs for vascular targeting agents (VTAs) in ...

May 27, 2005
OXiGENE to Present at Friedman Billings Ramsey Ninth Annual Growth Conference: June 1st at 11am

WALTHAM, Mass.--(BUSINESS WIRE)--May 27, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and ocular neovascular diseases, today announced that President and Chief Executive Officer Fred Driscoll will present an overview of t...

May 16, 2005
OXiGENE Announces Positive Phase Ib Update of CA4P with Radiotherapy at ASCO

-CA4P well tolerated with radiotherapy for lung and prostate cancers, anti-tumor activity observed- WALTHAM, Mass.--(BUSINESS WIRE)--May 16, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced that a clinical investigator studying the C...

May 13, 2005
OXiGENE Announces Presentation at ASCO of Positive Tumor Response Data in Phase Ib Trial of CA4P With Chemotherapy

Clinical Investigator Reports that CA4P in Combination with Carboplatin and/or Paclitaxel Indicates Anti-tumor Activity and No Unexpected Toxicity WALTHAM, Mass.--(BUSINESS WIRE)--May 13, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN...

Apr 27, 2005
OXiGENE Reports First-Quarter 2005 Operational and Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--April 27, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN): Recent Accomplishments: Announced positive data supporting clinical p...

Apr 19, 2005
OXiGENE Announces Positive New Preclinical Safety and Efficacy Data for CA4P at AACR

WALTHAM, Mass.--(BUSINESS WIRE)--April 19, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN): -CA4P in Combination Treatment Causes Complete Remissions in Anaplastic Thyroid Preclinical Model- ...

Apr 18, 2005
OXiGENE Announces New Preclinical Data Presented at AACR Supporting Development of Lead Vascular Targeting Agents; OXi4503 Shows Promising Preclinical Efficacy Data in Colorectal Tumors

CA4P's Safety Profile Further CharacterizedWALTHAM, Mass., Apr 18, 2005 (BUSINESS WIRE) -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced the presentation of positive new preclinical data at the 96th Annual Meeting of the American Association of Cancer ...

Apr 15, 2005
OXiGENE to Webcast First-Quarter 2005 Financial Results Conference Call April 27; Live Webcast to be Available at www.oxigene.com

WALTHAM, Mass.--(BUSINESS WIRE)--April 15, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) invites the public to listen to a live audio webcast of the Company's first-quarter 2005 financial results conference call at 10:00 a.m. ET Wednesday, April 27, 2005. President and Chief Executive Officer Fred Driscoll, Chief Financial Officer James Murph...

Apr 13, 2005
OXiGENE Announces Presentations on Lead Vascular Targeting Agents at American Association of Cancer Research

Seven Poster Presentations on CA4P and OXi4503 at AACR WALTHAM, Mass.--(BUSINESS WIRE)--April 13, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced the topics and schedules for seven poster presentations on OXiGENE compounds at the 96th Annual Meetin...

Mar 30, 2005
OXiGENE to Present at Lehman Brothers Eighth Annual Global HealthCare Conference: April 1st Presentation Available via Live Webcast

WALTHAM, Mass.--(BUSINESS WIRE)--March 30, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and ocular neovascular diseases, today announced that President and Chief Executive Officer Fred Driscoll will present at Lehman Brot...

FirstPrevious
...
34
NextLast
= add release to Briefcase